Objective To provide a single source for the best available estimates of the national
prevalence of arthritis in general and of selected musculoskeletal disorders (osteoarthritis, …

Background: Survival of scleroderma has changed since the renal crisis treatment has
become possible. Aims: To document the changes in survival and organ system causes of …

Of 397 systemic sclerosis (scleroderma) patients from the University of Pittsburgh, who had
serum determinations of both anti–Scl‐70 and anticentromere antibody (ACA), 26% had anti‐…

Objective. We sought to identify risk factors for developing severe restrictive lung disease
and to determine the time of onset and rate of progression in patients with systemic sclerosis (…

Objective The 1980 American College of Rheumatology (ACR) classification criteria for
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present …

Background We conducted a double-blind, randomized, placebo-controlled trial to determine
the effects of oral cyclophosphamide on lung function and health-related symptoms in …

Objective To determine the natural history and timing of severe involvement of the kidney,
heart, lung, gastrointestinal (GI) tract, and skin in patients with systemic sclerosis (SSc) and …

Pulmonary arterial hypertension (PAH) occurs as an idiopathic process or as a component
of a variety of disease processes, including chronic thromboembolic disease, connective …

OBJECTIVES: To describe the clinical, laboratory, and prognostic features associated with
the scleroderma-specific autoantibodies. METHODS: Using the Pittsburgh Scleroderma …

Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However, …